1. Home
  2. TRUP vs DBVT Comparison

TRUP vs DBVT Comparison

Compare TRUP & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$23.69

Market Cap

948.7M

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$16.28

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
DBVT
Founded
2000
2002
Country
United States
France
Employees
N/A
90
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
948.7M
948.8M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
TRUP
DBVT
Price
$23.69
$16.28
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$45.80
$32.04
AVG Volume (30 Days)
352.2K
257.3K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
295.65
10.26
EPS
0.11
N/A
Revenue
$1,439,305,000.00
$5,636,000.00
Revenue This Year
$11.79
$35.04
Revenue Next Year
$8.83
$2,360.78
P/E Ratio
$222.18
N/A
Revenue Growth
11.95
35.77
52 Week Low
$21.16
$8.50
52 Week High
$57.35
$26.19

Technical Indicators

Market Signals
Indicator
TRUP
DBVT
Relative Strength Index (RSI) 54.83 38.59
Support Level $21.16 $16.05
Resistance Level $29.24 $17.42
Average True Range (ATR) 0.90 0.97
MACD 0.38 0.02
Stochastic Oscillator 75.90 20.50

Price Performance

Historical Comparison
TRUP
DBVT

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: